Celgene Corporation CELG today announced the U.S. Food and Drug
Administration (FDA) has approved ABRAXANE^® (paclitaxel protein-bound
particles for injectable suspension) (albumin-bound) for the first-line
treatment of locally advanced or metastatic non-small cell lung cancer, in
combination with carboplatin, in patients who are not candidates for curative
surgery or radiation therapy.
“Non-small cell is the most common type of lung cancer, the leading cause of
cancer death in the United States,” said Dr. Mark A. Socinski, MD, Director,
Lung Cancer Section, Division of Hematology/Oncology, University of
Pittsburgh, and lead investigator of ABRAXANE phase II and phase III lung
cancer trials. “The FDA approval of ABRAXANE is exciting for healthcare
professionals because it offers an important new treatment option for all
types of non-small cell lung cancer patients, in an area that has seen few
treatment advancements in recent years.”
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in